Singapore, Jan. 5 -- ScinoPharm Taiwan has announced a landmark achievement in the global pharmaceutical landscape, securing US Food and Drug Administration (FDA) approval for Glatiramer Acetate Injection, a treatment for Multiple Sclerosis (MS), making it the only pharmaceutical company in Taiwan to achieve this historic milestone.

Multiple Sclerosis affects approximately 2.9 million people worldwide. According to the US National MS Society, there are nearly 1 million patients in the United States alone. Verified Market Reports estimates that the global market size for Glatiramer Acetate was $1.5 billion in 2024 and is projected to reach $2.8 billion by 2033.

In response to this significant opportunity, ScinoPharm has invested heavily ...